$LLY

Generating a unique summary for LLY…

AI-generated for information only — not investment advice.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Institutions hold 85.44% · insiders 0.16% · 5,882 institutions

Consensus score 1.70 (1 = strong buy, 5 = sell) · mean target 1315.56

• Truist SecuritiesBuymain2026-08-07
• Wells FargoOverweightmain2026-08-06
• Cantor FitzgeraldOverweightmain2026-08-06
• CitigroupBuymain2026-07-15
• BernsteinOutperformmain2026-07-14
• UBSBuymain2026-07-13
• GuggenheimBuymain2026-07-13
• B of A SecuritiesBuymain2026-07-10
• Truist SecuritiesBuymain2026-07-08
• Morgan StanleyOverweightmain2026-07-08

Next report: 2026-10-29

• 8-KCorporate Changes & Voting Matters2026-08-05Open
• 11-KAnnual report of employee stock purchase2026-06-23Open
• 8-KCorporate Changes & Voting Matters2026-05-20Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-11Open
• 8-KCorporate Changes & Voting Matters2026-05-07Open
• 10-QPeriodic Financial Reports2026-04-30Open
• DFAN14AProxy Statements2026-03-31Open
• DEF 14AProxy Statements2026-03-20Open
• PRE 14AProxy Statements2026-03-06Open
• 10-KPeriodic Financial Reports2026-02-12Open

• Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?

  Eli Lilly and Company’s (NYSE:LLY) Mounjaro has already become a major growth driver in diabetes treatment, and its latest FDA approval could strengthen that position by expanding what physicians can use the drug to accomplish. The FDA approved Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who […]

  Tue, 08 Sep 2026 00:14:26 +0000

• Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

  The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

  Mon, 07 Sep 2026 21:35:00 +0000

• Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

  Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

  Mon, 07 Sep 2026 14:03:00 +0000

• Eli Lilly’s $100B incretin opportunity: Is more upside coming?

  Investing.com -- Eli Lilly & Co is positioned for further growth in the booming obesity-drug market, with its Zepbound and Mounjaro treatments and a pipeline of next-generation therapies offering multiple avenues for upside, J.P. Morgan said in a research note.

  Sun, 06 Sep 2026 21:49:22 +0000

• Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock

  Is this big pharma stock still a buy for investors who aren't billionaires?

  Sun, 06 Sep 2026 09:11:00 +0000

• Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

  Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.

  Sat, 05 Sep 2026 21:08:00 +0000

• Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.

  Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.

  Sat, 05 Sep 2026 18:52:00 +0000

• Lilly Launches Foundayo in the UK as NICE Review Continues

  Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch […]

  Sat, 05 Sep 2026 00:47:26 +0000